Q2 EPS Estimates for Mersana Therapeutics Boosted by Wedbush

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Analysts at Wedbush increased their Q2 2025 EPS estimates for Mersana Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their prior estimate of ($0.26). Wedbush has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.52) EPS.

Separately, William Blair started coverage on shares of Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $3.67.

Mersana Therapeutics Price Performance

Shares of MRSN opened at $0.32 on Thursday. The stock has a market cap of $39.74 million, a P/E ratio of -0.52 and a beta of 1.32. Mersana Therapeutics has a 1 year low of $0.26 and a 1 year high of $2.88. The stock’s 50-day moving average price is $0.38 and its two-hundred day moving average price is $1.07. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

Institutional Investors Weigh In On Mersana Therapeutics

Several large investors have recently modified their holdings of the business. Wells Fargo & Company MN raised its stake in shares of Mersana Therapeutics by 40.3% in the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after purchasing an additional 19,368 shares during the period. SG Americas Securities LLC grew its holdings in shares of Mersana Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after buying an additional 25,058 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Mersana Therapeutics during the fourth quarter worth about $37,000. Geode Capital Management LLC raised its position in Mersana Therapeutics by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company’s stock valued at $3,493,000 after buying an additional 29,035 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Mersana Therapeutics by 115.7% in the 4th quarter. MetLife Investment Management LLC now owns 73,150 shares of the company’s stock valued at $105,000 after acquiring an additional 39,234 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.